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A B S T R A C T
Demonstration of bronchial hyperresponsiveness is a key feature in asthma diagnosis. Methacholine challenge
has proved to be a highly sensitive test to diagnose asthma in patients with chronic respiratory symptoms and
preserved baseline lung function (FEV1 > 70% pred.) but is time consuming and may sometimes reveal un-
pleasant to the patient.
We conducted a retrospective study on 270 patients recruited from the University Asthma Clinic of Liege. We
have compared the values of several lung function indices and fractional exhaled nitric oxide (FeNO) in pre-
dicting a provocative methacholine concentration ≤16 mg/ml on a discovery cohort of 129 patients (57 already
on ICS) and on a validation cohort of 141 patients (66 already on ICS).
In the discovery study (n = 129), 85 patients (66%) had a positive methacholine challenge with
PC20M ≤ 16 mg/ml. Those patients had lower baseline % predicted FEV1 (92% vs. 100%; p < 0.01), lower
FEV1/FVC ratio (79% vs. 82%; p < 0.05), higher RV/TLC ratio (114% vs. 100%; p < 0,0001), lower SGaw
(specific conductance) (0.76 vs. 0.95; p < 0,001) and higher FeNO (29 ppb vs. 19 ppb; p < 0,01). When
performing ROC curve the RV/TLC ratio provided the greatest AUC (0.74, p < 0.001), sGAW had intermediate
AUC of 0.69 (p < 0.001) while FeNO, FEV1 and FEV1/FVC ratio were modestly predictive (AUC of 0.65
(p < 0.05), 0,67 (p < 0.001) and 0,63 (p < 0.001). These results were confirmed in the validation study
(n = 141). Based on a logistic regression analysis, significant variables associated with positive methacholine
challenge were FeNO and RV/TLC (% Pred). A combined application of FeNO and RV/TLC (% Pred) for pre-
dicting the PC20M had a specificity of 85%, a sensitivity of 59% and an AUC of 0.79. In the validation study,
three variables (RV/TLC, FeNO and FEV1) were independently associated with positive methacholine challenge
and the combination of these three variables yielded a specificity of 77%, a sensitivity of 39% and an AUC of
0.77.
The RV/TLC ratio combined to FeNO may be of interest to predict significant methacholine bronchial hy-
perresponsiveness.
1. Introduction:
Excessive airway fluctuation is a fundamental feature in patient
with asthma. It could be demonstrated by a significant reversibility of
FEV1 (> 12% reversibility and 200 mL) following 400 µg inhaled sal-
butamol when FEV1 < 80% predicted or by bronchial hyperrespon-
siveness to methacholine challenge when FEV1 > 70% predicted [1].
Methacholine challenge test (MCT) has proved to be a highly sensitive
test to diagnose asthma in patients with chronic respiratory symptoms
and preserved baseline lung function [2,3]. However, the MCT is time
consuming and unpleasant for the patient. Recent surveys indicate that
wrong asthma diagnosis may be present up to 30% of patients who
received an asthma diagnosis in the community [4]. Therefore, finding
a test or a combination of tests that may predict a positive MCT could be
helpful for the clinician to diagnose asthma. On the other hand the
severity of bronchial hyperresponsiveness to methacholine was shown
to correlate with poor asthma control [5] and reducing the severity of
methacholine responsiveness with stepping up ICS improved asthma
control [6].
Here we have compared the values of several lung function indices
obtained during routine lung function assessment using body plethys-
mography together with measurement fractional exhaled nitric oxide
(FeNO) in predicting a provocative methacholine concentration
≤16 mg/ml. We also investigated the relationship between the severity
of methacholine bronchial hyperresponsiveness and baseline lung
function indices and FeNO among those who tested positive
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(PC20M ≤ 16 mg/ml). We first analysed the predicting values of FEV1,
FEV1/FVC ratio, specific conductance (sGaw), RV/TLC ratio and FeNO
on a discovery (or training) cohort of 129 patients (57 already on ICS)
and the results were confirmed on a validation cohort of 141 patients
(66 already on ICS) recruited from our asthma clinic.
2. Methods
We conducted a retrospective review of patients records from our
pulmonary function laboratory files. We selected patients from our
asthma clinic that had undergone spirometry, volume measurement by
body plethysmography, FeNO measurement and a methacholine chal-
lenge test from January 2017 to December 2017. We also selected a
second cohort of patients from January 2018 to December 2018 as a
validation cohort. These investigations were utilized to assess patients
with recurrent respiratory symptoms of cough, breathlessness and/or
wheezing and baseline FEV1 above 70% predicted. Almost half of these
patients were already receiving inhaled corticosteroids. Demographic
and functional patient characteristics are indicated in Table 1. The
demographic and functional characteristic of the validation cohort were
similar to those of the derivation cohort.
2.1. Exhaled nitric oxide
Exhaled nitric oxide was measured by a chemoluminescence ana-
lyser (NIOX, aerocrine, Stockholm, Sweden) at a flow rate of 50 mL/s.
This measure was conforming to the ATS/ERS task force’s re-
commendations [7].
2.2. Pulmonary function testing
All Pulmonary function tests were performed according to the ERS/
ATS criteria [8]. Spirometry was performed using an electronic spi-
rometer connected in real time to a computer (spirobank, MIR, Rome,
Italy). All manoeuvres were repeated three times and the best FEV1
value was kept by the software program (winspiro, MIR). Methacholine
chloride was purchased as powder (Provocholine 1280 mg; Metapharm,
Brantford, Ontario, Canada) and dissolved in NaCl 0.9% by the hospital
pharmacy to give appropriate concentrations. The methacholine chal-
lenge was performed by using a Hudson jet nebulizer (Hudson RCI;
Micro Mist, Research Triangle Park, NC) activated by an airflow rate of
6 L/minute and delivering 0.3 mL/minute. MCT was performed
according to a slightly modified Cockroft’s method. Patients succes-
sively inhaled by tidal breathing for 2 min fourfold increasing con-
centrations of methacholine chloride from 0.06 to 16 mg/ml as de-
scribed previously [9]. The aerosol was generated by a jet nebulizer
(Hudson, Temecula, CA, USA), whose characteristics were described
previously [10]. Spirometry data and RV/TLC were expressed as per-
cent predicted of normal reference value [11,12]. The specific con-
ductance was determined by implementing a least-squeared fit of the
line through the specific conductance loop at a defined fixed flow of 0.5
L/s [13,14].
2.3. Statistical analysis
The results were expressed as mean ± SD for continuous and
normally distributed variables while we preferred median and inter-
quartile ranges (IQR) for skewed distributions. For categorical vari-
ables, the number of observations and percentages were given in each
category. Comparison between the two groups was made with unpaired
t test or Mann-Witney test respectively when the normality test using
the method of Kolmogorov and Smirnov was passed or not. Correlations
were made using the Spearman coefficient of correlation.
Receiver-operating characteristic (ROC) curves were constructed to
define the accuracy of sGAW, RV/TLC, FEV1, FEV1/FVC and FENO to
predict a positive MCT. This method determines the accuracy of the
binary classification models and the area under the curve (AUC) is a
common measure of its exact evaluation. Cut-off was defined as the
value giving the best sum of sensitivity and specificity.
Logistic regression analysis was performed to assess the relationship
between the binary outcomes (PC20M) and five covariates, sGAW, RV/
TLC, FEV1, FEV1/FVC, FeNO. Ordinary estimation of unknown para-
meters in the model was calculated by GLM (generalized linear mixed
model) function by maximum likelihood. The ability of the equation to
predict a positive MCT was verified in an independent cohort of 141
patients recruited from 1 January 2018 to 31 December 2018. The re-
sults were considered to be significant at the 5% critical level
(p < 0.05). All analyses were performed using the R software.
3. Results
3.1. Ability of lung function indices and FeNO to predict positive
methacholine challenge in the discovery cohort
In the discovery cohort, 85/129 patients (66%) had a positive me-
thacholine challenge with PC20M ≤ 16 mg/ml (Table 1). Those pa-
tients had lower baseline percent predicted FEV1 (p < 0.01), lower
FEV1/FVC ratio (p < 0.05), higher RV/TLC ratio (p < 0.0001), lower
sGaw (specific conductance) (p < 0.001) and higher FeNO
(p < 0.01).
When performing ROC curve the RV/TLC ratio provided the
greatest AUC (0.74, p < 0.001) (Fig. 1) while AUC from sGaw, FEV1,
FEV1/FVC ratio and FeNO were modestly predictive ranging between
0.69 and 0.63 (Table 2). At a threshold of 99% predicted RV/TLC had a
sensitivity and specificity of 54% and 87% respectively (Table 2).
We then performed a logistic regression with the binary outcomes
(PC20M) and the 5 covariates (sGAW, RV/TLC, FeV1, FEV1/FVC and
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Ordinary estimation of unknown parameters in the model was cal-
culated by GLM (generalized linear mixed model) function by max-
imum likelihood. Estimation results are presented in Table 3.1. It
turned out that only two variables, RV/TLC and FeNO, had a significant
independent association with a positive MCT. Estimation results for the
Table 1
demographic and functional patient characteristics.
Cohort 1 Cohort 2
Number 129 141












Age 50 ± 15 51 ± 15








FeNO (ppb) 22 (14–47) 23 (14–39)
sGAW (1/kPa*s) 0.82 (0.63–1.01) 0.76 (0.58–0.98)
RV/TLC (% pred) 109 ± 17 106 ± 23
FEV1 (% pred) 95 ± 14 91 ± 16
FEV1/FVC (%) 80 ± 7 78 ± 8
Blood Neutrophils (1/µl) 3750 (2812–4662) 3767 (2999–4801)
Blood Eosinophils (1/µl) 201 (109–329) 151 (81–279)
Sputum Neutrophils (%) 63 (45–78) 78 (43–80)
Sputum Eosinophils (%) 1.8 (0.5–6.4) 1.6 (0.4–5.2)
Disease onset (years) 10 (3–25) 8 (3–26)
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significant variables are presented in Table 3.2. We then fit the model
again only taking into account the two significant variables. Compared
to the one with the five variables, the two variables model had a smaller
AIC (139.67 VS 141.62) which indicates a better-fitting model. There-
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The AUC, threshold, sensitivity, and specificity are reported in
Table 3.3. The Table 3.4 showed the Confusion Matrix. The ROC curve
is represented in Fig. 2.
A combined application of FeNO and RV/TLC (% Pred) for pre-
dicting the PC20M resulted in an area under curves equals to 0.79 with
the cut-off point of 0.464 and a sensitivity and specificity reaching 59%
and 85% respectively.
3.2. Ability of lung function indices and FeNO to predict positive
methacholine challenge in the validation cohort
The baseline demographic and lung function characteristics of the
patients of the validation cohort (cohort 2) were very similar to the
cohort 1 and shown in Table 1.
In the validation cohort it is again RV/TLC ratio that provided the
greatest AUC (0.75) to predict positive PC20M (Fig. 3). At a threshold of
102% predicted, RV/TLC had a sensitivity and a specificity of 71% and
68% respectively (Table 4). Other lung function indices performed less
well with lower AUC and the FeNO AUC was even not significant
(Table 4). After multiple logistic regression, three variables (RV/TLC,
FeNO and FEV1) had a significant predicting effect on the results of
PC20M. Estimation results are presented in Tables 5.1 and 5.2 respec-
tively with and without non-significant variables. We performed a lo-
gistic regression with the binary outcomes (PC20M) and these 3 cov-
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A combined application of FeNO, RV/TLC (% Pred) and FEV1 (%
Pred) for predicting the PC20M resulted in an AUC of 0.77 and a cut-off
point of 0.363 yielding a sensitivity and a specificity of 69% and 77%
respectively. The AUC, threshold, sensitivity, and specificity are re-
ported in Table 5.3. The table 5.4 showed the Confusion Matrix. The
ROC curve is represented in Fig. 4.
When the combined variables were compared each of individual
variables, the combination of variables was superior to the FeNO alone
in terms of specificity, was superior to the RV/TLC (% Pred) alone in
terms of sensitivity. Combination of variables provided a greater AUC
compared to the variables taken alone.
3.3. Correlation between PC20M and lung function indices and FeNO
Among the patients who tested positive to methacholine
Fig. 1. Receiver-operating characteristic curve (ROC) for the discovery cohort to determine the RV/TLC value which best identified a positive methacholine
challenge test (MCT) with PC20M ≤ 16 mg/ml. The optimum cut-off point was 99% pred. (AUC 0.735, sensitivity 54.5%, specificity 87%, VPP 78.7%, VPN 68.6%,
P < 0.001).
Table 2
Values derived from the ROC curves of lung function indices and FeNO for a positive methacholine challenge in the discovery cohort (Cohort 1).
AUC Threshold Sensitivity Specificity VPP VPN P-value
RV/TLC (% pred) 0.735 99 0.545 0.870 78.7% 68.6% <0.001
sGAW (1/kPa*s) 0.689 0.73 0.864 0.494 87.5% 46.9% <0.001
FeNO (ppb) 0.645 25 0.773 0.576 83.1% 48.6% <0.05
FEV1 (% pred) 0.667 98 0.614 0.718 78.2% 52.9% <0.001
FEV1/FVC (%) 0.626 77 0.818 0.459 83% 43.9% <0.001
Table 3.1
Parameter estimation for logistic regression on the discovery cohort for the five
indices model.
Odds ratio Confidence Interval P-value Result
Lower Upper
Intercept 8.707 0.021 3621.31 0.555 Not Significant
FeNO 0.973 0.956 0.990 0.009 Significant
(P < 0.05)
sGAW 3.238 0.959 10.938 0.112 Not Significant
RV/TLC 0.955 0.931 0.981 0.004 Significant
(P < 0.001)
FEV1 1.017 0.988 1.046 0.342 Not Significant
FEV1/FVC 1.003 0.945 1.064 0.929 Not Significant
AIC: 141.62.
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(PC20M ≤ 16 mg/ml) in the training cohort (cohort 1), the magnitude
of PC20M was significantly and inversely correlated with FeNO (r = -
0.37; p < 0.001) (Fig. 5a) but was poorly correlated with the other
indices: FEV1 (r = 0.06; p > 0.5), FEV1/FVC (r = 0.20; p = 0.06),
sGaw (r = 0.11; p > 0.1), RV/TLC (r = -0,18; p > 0.05). In the
validation cohort (cohort 2) the magnitude of PC20M was again in-
versely related to FeNO (r = -0.22, p < 0.05) (Fig. 5b), positively
related to sGaw (r = 0.25, p < 0.05) but not significantly related to
FEV1 (r = 0.15), FEV1/FVC (r = 0.11) and RV/TLC (r = -0.08)
(p > 0.05 for all).
4. Discussion
Our study shows that a combination of RV/TLC measured by ple-
thysmography and FeNO provides the best strategy to predict the po-
sitivity of a methacholine challenge in patients with symptoms sug-
gestive of asthma. It indicates that both gas trapping and epithelial cell
activation may play key roles in determining the presence of bronchial
hyperresponsiveness.
Our data regarding the ratio RV/TLC are in keeping with what
Stanbrook et al reported more than 25 years ago [15]. They found that
RV/TLC was a specific (81%) but insensitive (29%) index of positive
methacholine challenge test with a threshold set at 120% predicted. In
our study sensitivity was clearly higher and above 50% with specificity
above 60% in both cohorts. This is explained by the differences between
cut-points. Ours were defined by ROC curves and turned around 100%
in both cohorts. Therefore, our cut-points are much lower than the
arbitrarily 120% reported in the study of Stanbrook et al. As Stanbrook
et al did not give much details about their patients, likely some of these
patients had COPD. Our cohorts were made of patients with both sus-
pected asthma and confirmed asthma in whom methacholine challenge
was performed to assess the extent of bronchial hyperresponsiveness as
a component of the disease. Overall Stanbrook’study and ours point to
the interest of looking at the index RV/TLC in asthmatics or in patients
with suspicion of asthma. Yet, this parameter is seldom evoked in
asthma literature while it has long been recognised as an important sign
of lung hyperdistension in COPD. Moreover, our current study also
aligns with the recent ATLANTIS study from Postma et al showing re-
newed interest for small airway dysfunction indices, and for RV/TLC in
particular, which appeared to correlate with asthma control [16].
In our study, traditional lung function indices reflecting more
proximal airway obstruction like the ratio FEV1/FVC or sGaw per-
formed less well than RV/TLC and, interestingly, did not emerge con-
vincingly in the multiple logistic regression model. Our results would
suggest that baseline distal airway obstruction, reflected by increased
RV/TLC, may be critical in predicting positive methacholine challenge.
Table 3.2
Parameter estimation for logistic regression on the discovery cohort for the two indices model.
Odds ratio Confidence Interval P-value Result
Lower Upper
Intercept 6.433 42.489 9109.72 < 0.001 Significant (P < 0.001)
RV/TLC −0.058 0.921 0.967 < 0.001 Significant (P < 0.001)
FeNO −0.029 0.954 0.987 0.004 Significant (P < 0.05)
AIC: 139.67.
Table 3.3
Outputs of ROC curve for two full and final models (Cohort 1).
AUC Threshold Sensitivity Specificity VPP VPN P-value Accuracy
All five Variables 0.805 0.379 0.75 0.753 85.3% 61.1% <0.001 0.75
FeNO RV/TLC 0.787 0.464 0.591 0.847 80% 66.7% <0.001 0.76
Table 3.4
Confusion Matrix (Prediction-accuracy output) (Cohort 1).
Real value
0 1
Predicted 0 72 18
Value 1 13 24
Accuracy: 0.759
Fig. 2. Receiver-operating characteristic curve
(ROC) for the discovery cohort to determine the
combination of RV/TLC and FeNO value which
best identified a positive methacholine challenge
test (MCT) with PC20M ≤ 16 mg/ml. The op-
timum cut-off point was 0.464 (AUC 0.787, sen-
sitivity 59.1%, specificity 84.7%, P < 0.001).
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We can speculate that methacholine deposition in the airways may be
more proximal if the RV/TLC is higher, thereby increasing the fall in
FEV1 upon methacholine inhalation, which is an index better reflecting
changes in calibre of intermediate to large airways during the chal-
lenge. However, if RV/TLC appears to be good at predicting positive
methacholine challenge, it failed to correlate with the magnitude of
bronchial hyperresponsiveness in the patients who had a PC20M below
16 mg/ml, which is in keeping with what was reported by Stanbrook
et al.
The link between asthma and FeNO has been extensively studied
over the last 20 years. We have previously reported that FeNO had a
poor sensitivity but a good specificity and positive predictive value for a
PC20 < 16 mg/ml in patients referred by chest physicians to a lung
function laboratory for symptoms suggestive of asthma and normal
spirometry [17]. Overall recent meta-analysis has shown that FeNO has
low sensitivity but acceptable specificity to make an asthma diagnosis
[18]. The interest of our current study is that it shows that, though not
impressive in ROC curve, the contribution of FeNO emerged after
multivariate logistic regression. This would suggest that the effect of
FeNO may be counteracted by other variables to which it is linked.
FeNO is seen as a biomarker of epithelial cell activation in a T2 en-
vironment and has been related to the magnitude of airway eosinophilic
inflammation [19]. However, FeNO has also been shown to be depen-
dent on the airway calibre, with a reduction of its level in exhaled air
when bronchial obstruction develops and reduces airway calibre [20].
As lower baseline airway calibre also contributes to bronchial hyper-
esponsiveness as indicated by the predictive value of baseline FEV1 on
the positivity of PC20M, it may explain why FeNO, though not per-
forming strong in the prediction of positive PC20M, emerged as sig-
nificant contributor after multiple logistic regression. Our results also
show that combining RV/TLC and FeNO in a multiple logistic model
improves with an AUC reaching 0.79 and an accuracy of 76%.
Interestingly, FeNO was the index that correlated the most convin-
cingly with the severity of bronchial hyperresponsiveness among the
subjects who tested positive to methacholine challenge. This confirms,
in a mixed population including ICS treated patients, studies that in-
vestigated corticoid naïve patients [21,3]. This observation supports the
link between epithelial cell activation and smooth muscle airway re-
activity.
Finally we acknowledge that our two cohorts of patients were a mix
of T2 and non T2 mild to moderate asthma with a large range in FeNO
values as well as in sputum and blood eosinophil counts. The existence
the two types of asthma is a well accepted observation today, both in
mild to moderate and in a severe asthma [22–24]. The average values
Fig. 3. Receiver-operating characteristic curve
(ROC) for the validation cohort to determine the
RV/TLC value which best identified a positive
methacholine challenge test (MCT) with
PC20M ≤ 16 mg/ml. The optimum cut-off point
was 102% pred. (AUC 0.748, sensitivity 71.1%,
specificity 67.7%, VPP 83.3%, VPN 50.8%,
P < 0.001).
Table 4
Values derived from the ROC curves of lung function indices and FeNO for a positive methacholine challenge in the validation cohort (cohort 2).
AUC Threshold Sensitivity Specificity VPP VPN P-value
RV/TLC (% pred) 0.748 102 0.711 0.677 83.3% 50.8% <0.001
sGAW (1/kPa*s) 0.620 0.87 0.511 0.708 75.6% 45.1% <0.05
FeNO (ppb) 0.559 32 0.867 0.385 86% 39.8% 0.13
FEV1 (% pred) 0.689 99 0.511 0.833 78.4% 59% <0.001
FEV1/FVC (%) 0.683 79 0.689 0.667 82.1% 49.2% <0.001
Table 5.1
Parameter estimation for logistic regression on the validation cohort for the five
indices model.
Odds ratio Confidence Interval P-value Result
Lower Upper
Intercept 0.215 0.0007 69.63 0.661 Not Significant
FeNO 0.983 0.967 0.999 0.083 Significant
(P < 0.1)
sGAW 0.792 0.244 2.571 0.744 Not Significant
RV/TLC 0.971 0.950 0.992 0.025 Significant
(P < 0.05)
FEV1 1.03 1.001 1.061 0.087 Significant
(P < 0.1)
FEV1/FVC 1.021 0.962 1.084 0.561 Not Significant
AIC: 161.15
Table 5.2
Parameter estimation for logistic regression on the validation cohort for the
three indices model.
Odds ratio Confidence Interval P-value Result
Lower Upper
Intercept 0.774 0.018 33.229 0.911 Not Significant
RV/TLC 0.970 0.951 0.989 0.012 Significant (P < 0.05)
FeNO 0.983 0.967 0.998 0.074 Significant (P < 0.1)
FEV1 1.034 1.006 1.061 0.042 Significant (P < 0.05)
AIC: 157.5.
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of inflammatory biomarkers in the two cohorts presented in this study
are rather similar to the ones we previously reported from patients
recruited from the same ambulatory care facilities [25]. Thus, we be-
lieve our finding applies to a general asthmatic population recruited in
a secondary care centre.
We conclude that taking into account both an index of lung dis-
tension and airway epithelial cell activation may help the clinician to
predict the presence of bronchial hyperresponsiveness to methacholine
in patients. Combining a lung function index with an airway in-
flammatory biomarker is a suitable strategy to approach the existence
of bronchial hyperresponsiveness.
CRediT authorship contribution statement
N. Bougard: Writing - original draft, Visualization, Writing - review
& editing. H. Nekoee: Methodology, Formal analysis, Validation. F.
Schleich: Investigation. F. Guissard: Resources, Data curation. V.
Paulus: Resources, Data curation. AF Donneau: Software, Supervision.
R. Louis: Conceptualization, Validation, Project administration,
Supervision.
Acknowledgment
We acknowledge the financial support of a federal government
grant EOS (excellence of science), Belgium (30565447).
Table 5.3
Outputs of ROC curve for two full and final models (Cohort 2).
AUC Threshold Sensitivity Specificity VPP VPN P-value Accuracy




0.769 0.363 0.689 0.771 84% 58.5% <0.001 0.745
Table 5.4
Confusion Matrix (Prediction-accuracy output) (Cohort 2).
Real value
0 1
Predicted 0 74 14
Value 1 22 31
Accuracy: 0.745.
Fig. 4. Receiver-operating characteristic curve
(ROC) for the validation cohort to determine the
combination of RV/TLC, FeNO and FEV1 value
which best identified a positive methacholine
challenge test (MCT) with PC20M ≤ 16 mg/ml.
The optimum cut-off point was 0.363 (AUC
0.769, sensitivity 68.9%, specificity 77.1%,
P < 0.001).
Fig. 5. Correlation between FeNO and PC20 methacholine in the cohort 1
(upper panel) and the cohort 2 (lower panel). Rs is the spearman coefficient of
correlation.
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